Strategies to improve recovery in acute ischemic stroke patients: Iberoamerican Stroke Group Consensus

International Journal of Stroke

Volumn 9, Issue 4, 2014, Pages 503-513

  Alonso de Lecinana M ^a   Gutierrez Fernandez M ^b   Romano, M ^c   Cantu Brito C ^d   Arauz, A ^e   Olmos, Le ^f   Ameriso, Sf ^f   Diez Tejedor E ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c CEMIC   (Argentina)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^f FLENI   (Argentina)

Author keywords

Brain plasticity; Brain protection; Brain repair; Ischemic stroke

Indexed keywords

ARTICLE; BLOOD CLOT LYSIS; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN PROTECTION; COGNITIVE DEFECT; CONSENSUS; DEVELOPED COUNTRY; HUMAN; LIFE EXPECTANCY; NERVE CELL PLASTICITY; PRIORITY JOURNAL; REHABILITATION CARE; REPERFUSION; STROKE PATIENT; BRAIN; COMPLICATION; CONVALESCENCE; DRUG EFFECTS; ENDOVASCULAR SURGERY; FIBRINOLYTIC THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SOUTH AND CENTRAL AMERICA; STROKE;

NEUROPROTECTIVE AGENT;

BRAIN; BRAIN ISCHEMIA; CONSENSUS; ENDOVASCULAR PROCEDURES; HUMANS; LATIN AMERICA; NEUROPROTECTIVE AGENTS; RECOVERY OF FUNCTION; STROKE; THROMBOLYTIC THERAPY;

EID: 84899897387     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12070     Document Type: Article

References (125)

1. del Zoppo GJ. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009; 158:972-982.
2. Gutiérrez M, Merino JJ, Alonso de Leciñana M, Díez-Tejedor E. Cerebral protection, brain repair, plasticity and cell therapy in ischemic stroke. Cerebrovasc Dis 2009; 27:177-186.
3. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol 2008; 63:549-560.
4. Cabral NL, Gonçalves AR, Longo AL etal. Incidence of stroke subtypes, prognosis and prevalence of risk factors in Joinville, Brazil: a 2 year community based study. J Neurol Neurosurg Psychiatry 2009; 80:755-761.
5. Lavados PM, Sacks C, Prina L etal. Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: a 2-year community-based prospective study (Piscis project). Lancet 2005; 365:2206-2215.
6. Cantu-Brito C, Majersik JJ, Sánchez BN etal. Door-to-door capture of incident and prevalent stroke cases in Durango, Mexico: the Brain Attack Surveillance in Durango Study. Stroke 2011; 42:601-606.
7. Hochmann B, Coelho J, Segura J, Galli M, Ketzoian C, Pebet M. Incidencia del accidente cerebrovascular en la ciudad de Rivera, Uruguay. Rev Neurol 2006; 43:78-83.
8. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
9. Hacke W, Kaste M, Fieschi C etal. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352:1245-1251.
10. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischemic stroke. Cochrane Database Syst Rev 2009; (4):DC:000213.
11. Wahlgren N, Ahmed N, Dávalos A etal. SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275-282.
12. Hacke W, Kaste M, Bluhmki E etal. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
13. Ahmed N, Wahlgren N, Grond M etal. SITS investigators implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS_ISTR. Lancet Neurol 2010; 9:866-874.
14. Adams HP Jr, del Zoppo G, Alberts MJ etal. American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-1711.
15. Haley EC Jr, Thompson JL, Grotta JC etal. Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010; 41:707-711.
16. Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012; 165:75-89.
17. Fiebach JB, Al-Rawi Y, Wintermark M etal. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012; 43:1561-1566.
18. Furlan A, Higashida R, Weschler L etal. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. JAMA 1999; 282:2003-2011.
19. Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke 2010; 41:932-937.
20. Mattle HP, Arnold M, Georgiadis D etal. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008; 39:379-383.
21. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R; Boccardi E for the SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013; 368: 904-913.
22. Meyers PM, Schumacher HC, Higashida RT etal. American Heart Association. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association. Circulation 2009; 119:2235-2249.
23. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013; 368:893-903.
24. Gobin YP, Starkman S, Duckwiler GR etal. MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke 2004; 35:2848-2854.
25. Smith WS, Sung G, Saver J etal. Multi MERCI Investigators. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39:1205-1212.
26. Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40:2761-2768.
27. Koh JS, Lee SJ, Ryu CW, Kim HS. Safety and efficacy of mechanical thrombectomy with solitaire stent retrieval for acute ischemic stroke: a systematic review. Neurointervention 2012; 7:1-9.
28. Díez-Tejedor E, Fuentes B. Homeostasis as basis of acute stroke treatment: stroke units are the key. Cerebrovasc Dis 2005; 20:129-134.
29. Seenan P, Long M, Langhorne P. Stroke units in their natural habitat: systematic review of observational studies. Stroke 2007; 38:1886-1892.
30. Alonso de Leciñana M, Egido JA, Casado I etal. on behalf of the Comité ad hoc del grupo de estudio de enfermedades cerebrovasculares de la SEN. Guidelines for the treatment of acute ischaemic stroke. Neurologia. 2011 Dec 6. [Epub ahead of print] PubMed PMID: 22152803.
31. Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004; 35:520-526.
32. Vemmos KN, Tsivgoulis G, Spengos K etal. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004; 255:257-265.
33. International Society of Hypertension Writing Group. International Society of Hypertension: statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21:665-672.
34. Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke 2000; 31:404-409.
35. den Hertog HM, van der Worp HB, van Gemert HM etal. PAIS Investigators. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 2009; 8:434-440.
36. Den Hertog HM, van der Worp HB, Tseng MC, Dippel DW. Cooling therapy for acute stroke. Cochrane Database Syst Rev 2009; (1):CD001247.
37. Fuentes B, Castillo J, San José B etal. Stroke Project of the Cerebrovascular Diseases Study Group, Spanish Society of Neurology. The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) study. Stroke 2009; 40:562-568.
38. Fuentes B, Ortega-Casarrubios MA, Sanjosé B etal. Stroke Project of the Cerebrovascular Diseases Study Group Spanish Society of Neurology. Persistent hyperglycemia >155 mg/dL in acute ischemic stroke patients: how well are we correcting it? Implications for outcome. Stroke 2010; 41:2362-2365.
39. Alvarez-Sabín J, Molina CA, Montaner J etal. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator - treated patients. Stroke 2003; 34:1235-1241.
40. Ribó M, Molina C, Montaner J etal. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005; 36:1705-1709.
41. Gray CS, Hildreth AJ, Sandercock PA etal. GIST Trialists Collaboration. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007; 6:397-406.
42. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008; 55:363-389.
43. The internet stroke center. Stroke trials. http://www.strokecenter.org/trials
44. Goslinga H, Eijzenbach V, Heuvelmans JH etal. Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke. Stroke 1992; 23:181-188.
45. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke II: neurologic outcome and efficacy analysis. Stroke 2006; 37:2107-2114.
46. Ginsberg MD, Palesch YY, Hill MD. The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans 2006; 34:1323-1326.
47. Lampl Y, Boaz M, Gilad R etal. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69:1404-1410.
48. Blanco M, Nombela F, Castellanos M etal. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69:904-910.
49. Fuentes B, Martínez-Sánchez P, Díez-Tejedor E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009; 27:126-133.
50. Martínez-Sánchez P, Rivera-Ordóñez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, Díez-Tejedor E. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol 2009; 16:127-133.
51. Biffi A, Devan WJ, Anderson CD etal. Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke 2011; 42:1314-1319.
52. Gutiérrez-Fernández M, Fuentes B, Rodríguez-Frutos B, Ramos-Cejudo J, Vallejo-Cremades MT, Díez-Tejedor E. Trophic factors and cell therapy to stimulate brain repair after ischemic stroke. J Cell Mol Med 2012; 16:2280-2290.
53. Hurtado O, Lizasoain I, Moro MA. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke 2011; 42:S33-35.
54. Alonso de Leciñana M, Gutiérrez M, Roda JM, Carceller F, Díez-Tejedor E. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci 2006; 247:121-129.
55. Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B etal. CDP-Choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int 2012; 60:310-317.
56. Dávalos A, Castillo J, Alvarez-Sabín J etal. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002; 33:2850-2857.
57. Dávalos A, Alvarez-Sabín J, Castillo J etal. for the International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380:349-357.
58. Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci 2007; 25:25-31.
59. Zhang C, Chopp M, Cui Y etal. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 2010; 88:3275-3281.
60. Rodríguez Frutos B, Gutierrez Fernández M, Alvarez Grech J etal. Therapeutic effect of brain derived peptide and stem cells in acute cerebral infarct: experimental study in rats. Cerebrovasc Dis 2010; 29:317.
61. Ladurner G, Kalvach P, Moessler H, Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke. A randomised controlled trial. J Neural Transm 2005; 112:415-428.
62. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012; 43:630-636.
63. Lang W, Stadler CH, Poljakovic Z, Fleet D; Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke 2013; 8:95-104.
64. Wada K, Sugimori H, Bhide PG, Moskowitz MA, Finklestein SP. Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats. Stroke 2003; 34:2722-2728.
65. Bogousslavsky J, Victor SJ, Salinas EO etal. European-Australian Fiblast (Trafermin) in Acute Stroke Group. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 2002; 14:239-251.
66. Minnerup J, Heidrich J, Rogalewski A, Schäbitz WR, Wellmann J. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009; 40:3113-3120.
67. Ehrenreich H, Hasselblatt M, Dembowski C etal. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505.
68. Ehrenreich H, Weissenborn K, Prange H etal. EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40:e647-e656.
69. Popa-Wagner A, Stöcker K, Balseanu AT etal. Effects of granulocyte-colony stimulating factor after stroke in aged rats. Stroke 2010; 41:1027-1031.
70. England TJ, Abaei M, Auer DP etal. Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the stem cell trial of recovery enhancement after stroke 2 randomized controlled trial. Stroke 2012; 43:405-411.
71. Ringelstein EB, The AXIS-2 study group. AXIS-2 study: AX200 for the treatment of acute ischemic stroke. ISC 2012, New Orleans, 3 February 2012.
72. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999; 30:2592-2597.
73. Warach S, Pettigrew LC, Dashe JF etal. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging.Citicoline 010 Investigators. Ann Neurol 2000; 48:713-722.
74. Jianu DC, Muresanu DF, Bajenaru O etal. Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. J Med Life 2010; 3:297-307.
75. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35:1732-1737.
76. Lindvall O, Kokaia Z. Stem cell research in stroke: how far from the clinic? Stroke 2011; 42:2369-2375.
77. Stroemer P, Patel S, Hope A, Oliveira C, Pollock K, Sinden J. The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion. Neurorehabil Neural Repair 2009; 23:895-909.
78. Shen CC, Lin CH, Yang YC, Chiao MT, Cheng WY, Ko JL. Intravenous implanted neural stem cells migrate to injury site, reduce infarct volume, and improve behavior after cerebral ischemia. Curr Neurovasc Res 2010; 7:167-179.
79. Daadi MM, Davis AS, Arac A etal. Human neural stem cell grafts modify microglial response and enhance axonal sprouting in neonatal hypoxic-ischemic brain injury. Stroke 2010; 41:516-523.
80. Kondziolka D, Steinberg GK, Wechsler L etal. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg 2005; 103:38-45.
81. Yang M, Wei X, Li J, Heine LA, Rosenwasser R, Iacovitti L. Changes in host blood factors and brain glia accompanying the functional recovery after systemic administration of bone marrow stem cells in ischemic stroke rats. Cell Transplant 2010; 19:1073-1084.
82. Parker AM, Katz AJ. Adipose-derived stem cells for the regeneration of damaged tissues. Expert Opin Biol Ther 2006; 6:567-578.
83. Suarez-Monteagudo C, Hernandez-Ramirez P, Alvarez-Gonzalez L etal. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci 2009; 27:151-161.
84. Honmou O, Houkin K, Matsunaga T etal. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011; 134:1790-1807.
85. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57:874-882.
86. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 28:1099-1106.
87. Taguchi A, Soma T, Tanaka H etal. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004; 114:330-338.
88. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res 2002; 90:284-288.
89. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Regeneration of the ischemic brain by engineered stem cells: fuelling endogenous repair processes. Brain Res Rev 2009; 61:1-13.
90. Nakano-Doi A, Nakagomi T, Fujikawa M etal. Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction. Stem Cells 2010; 28:1292-1302.
91. Leu S, Lin YC, Yuen CM etal. Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. J Transl Med 2010; 8:63.
92. Gutiérrez-Fernández M, Rodríguez-Frutos B, Álvarez-Grech J etal. Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats. Neuroscience 2011; 175:394-405.
93. Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, Díez-Tejedor E. Allogenic mesenchymal stem cells in experimental ischaemic stroke. Translation to the clinic? Hayat MA (ed.): Stem Cells and Cancer Stem Cells. NY, USA, Springer Science + Business Media, 2012:117-127.
94. Duncan PW, Zorowitz R, Bates B etal. Management of adult stroke rehabilitation care. A clinical practice guideline. The Stroke Council of the American Heart Association. Stroke 2005; 36:e100-143.
95. Wolf SL, Blanton S, Baer H, Breshears J, Butler AJ. Repetitive task practice: a critical review of constraint-induce movement therapy in stroke. Neurologist 2002; 8:325-338.
96. Page SJ, Sisto S, Levine P, McGrath RE. Efficacy of modified constraint-induce movement therapy in chronic stroke: a single-blinded randomized controlled trial. Arch Phys Med Rehabil 2004; 85:14-18.
97. Wolf SL, Winstein CJ, Miller JP etal. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke. The EXCITE Randomized Clinical Trial. JAMA 2006; 296:2095-2104.
98. Ward NS, Cohen LG. Mechanisms underlying recovery of motor function after stroke. Arch Neurol 2004; 61:1844-1848.
99. Floel A, Hummel F, Duque J, Knecht S, Cohen LG. Influence of somatosensory input on motor function in patients with chronic stroke. Ann Neurol 2004; 56:206-212.
100. Conforto AB, Kaelin-Lang A, Cohen LG. Increase in hand muscle strength of stroke patients after somatosensory stimulation. Ann Neurol 2002; 51:122-125.
101. Schambra HM, Sawaki L, Cohen LG. Modulation of excitability of human motor cortex (M1) by 1 Hz transcranial magnetic stimulation of the contralateral M1. Clin Neurophysiol 2003; 114:130-133.
102. Duncan PW, Sullivan KJ, Behrman AL etal. LEAPS Investigative Team. Body weight-supported treadmill rehabilitation after stroke. N Engl J Med 2011; 364:2026-2036.
103. Martinsson L, Hårdemark H, Eksborg S. Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev 2007; (1):CD002090.
104. Seniów J, Litwin M, Litwin T, Leśniak M, Czlonkowska A. New approach to the rehabilitation of poststroke focal cognitive syndrome: effect of levodopa combined with speech and language therapy on functional recovery from aphasia. J Neurol Sci 2009; 283:214-218.
105. Chollet F, Tardy J, Albucher JF etal. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10:123-130.
106. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 2008; 22:311-314.
107. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008; (4):CD003437.
108. Narushima K, Paradiso S, Moser DJ, Jorge R, Robinson RG. Effect of antidepressant therapy on executive function after stroke. Br J Psychiatry 2007; 190:260-265.
109. Berthier ML, Hinojosa J, Martin Mdel C, Fernandez I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 2003; 60:1218-1219.
110. Berthier ML, Pujol J, Gironell A etal. Beneficial effect of donepezil on sensorimotor function after stroke. Am J Phys Med Rehabil 2003; 82:725-729.
111. Berthier ML, Green C, Lara JP etal. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol 2009; 65:577-585.
112. Wilson MS, Gibson CJ, Hamm RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil 2003; 82:871-879.
113. Sims JS, Jones TA, Fulton RL. Benzodiazepines effects on recovery of function linked to transneuronal morphological events. Soc Neurosci Abstr 1990; 16:342.
114. O'Brien JT, Erkinjuntti T, Reisberg B etal. Vascular cognitive impairment. Lancet Neurol 2003; 2:89-98.
115. Sachdev PS, Chen X, Brodaty H, Thompson C, Altendorf A, Wen W. The determinants and longitudinal course of post-stroke mild cognitive impairment. J Int Neuropsychol Soc 2009; 15:915-923.
116. Erkinjunnti T, Inzitari D, Pantoni L etal. Research criteria for subcortical vascular dementia in clinical trials. J Neural Tranms Suppl 2000; 59:23-30.
117. Nyenhuis D, Petersen R, Schneider JA etal. Stroke Association for Healthcare Professionals From the American Heart Association/American Vascular Contributions to Cognitive Impairment and Dementia: a statement. Stroke 2011; 42:2672-2713.
118. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283-1290.
119. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69:448-458.
120. Wilkinson D, Doody R, Helme R etal. Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61:479-486.
121. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002; 203-204:141-146.
122. Narasimhalu K, Effendy S, Sim CH etal. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand 2010; 121:217-224.
123. Alvarez-Sabín J, Román GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke 2011; 42:S40-43.
124. Garcia-Cobos R, Frank-Garcia A, Gutierrez Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci 2010; 299:188-192.
125. Muresanu DF, Alvarez XA, Moessler H etal. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. J Neurol Sci 2010; 299:179-183.